Table 3. Participant characteristics in studies of children with biopsy-proven NAFLD.

Study	Study sample size	Age, years	Female sex, %	ALT, U/L	AST, U/L	GGT, U/L	Liver fat measure, %	Steatosis grade, % or mean (SD)	Participants with NASH, n (%)
Lavine 2011 [41]	173	13.1	19	123	71	51	—	2.2 (0.8)	73 (42%)
Pacifico 2015 [42]	51	10.9	41	56	—	—	14.0–15.5a	Grade 1: 28 Grade 2: 33 Grade 3: 39	33 (65%)
Della Corte 2016 [43]	43	12.8	56	46	31	21	—	Grade 1: 21 Grade 2: 49 Grade 3: 30	14 (33%)
Zöhrer 2016 [44]	40	13.2	40	52	35	—	—	Grade 1: 37.5 Grade 2: 40 Grade 3: 22.5	40 (100%)
Schwimmer 2017 [45]	169	13.7	30	123	71	47	21.1 (9.8)b,c	2.4 (0.7)	44 (26%)
Schwimmer 2019 [5]	40	13.1	0	73–82d	39–44e	42–53f	23 (9.7)c	—	11 (28%)
Vos 2022 [46]	83	13	19	120	64	52	—	Grade 1: 12 Grade 2: 29 Grade 3: 59, 2.5 (0.7)	20 (24%)

Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma‐glutamyltransferase; NASH, non-alcoholic steatohepatitis;—, no data available.

^aHepatic fat fraction assessed by MRI. The median hepatic fat fraction in the intervention and placebo groups ranged from 14.0–15.5%.

^bMRI-PDFF available for 110 participants.

^cHepatic steatosis assessed by MRI-PDFF.

^dThe median ALT in the intervention and placebo groups ranged from 73–82 U/L.

^eThe median AST in the intervention and placebo groups ranged from 39–44 U/L.

^fThe median GGT in the intervention and placebo groups ranged from 42–53 U/L.